Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Clinical trial NCT04948333 · COMPLETED

Trial details

NCT number: NCT04948333
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia

Start date: 2021-10-13
Primary completion: 2024-03-12
Enrollment: 199

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.